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Arthritis models
P1
IL-21 modulates cytokine levels in murine collagen-induced
arthritis and contributes to disease pathology
DA Young, M Hegen, H Ma, L Napierata, J Lamothe, M Senices,
L Lowe, M Collins, C Nickerson-Nutter
Inflammation, Wyeth Research, Cambridge, MA, USA
Arthritis Research & Therapy 2007, 9(Suppl 3):P1 
(doi: 10.1186/ar2227)
Background IL-21 is secreted by activated T cells and modulates
immune cell functions with both proinflammatory and anti-inflam-
matory effects. IL-21 receptor (IL-21R), homologous to IL-2Rβ and
IL-4Rα, associates with the gamma common chain upon ligand
binding. It was recently described that IL-21R is overexpressed in
the inflamed synovial membrane and on leucocytes of rheumatoid
arthritis patients.
Objective Previously we have shown that blockade of the IL-21
pathway with soluble IL-21R-Fc resulted in a reduction of clinical
signs of arthritis in rodent models. To understand potential mecha-
nisms of IL-21 regulation in arthritis, we analyzed serum immuno-
globulin levels, and cytokine expression in the paws, serum, and
collagen-restimulated splenocytes, in response to IL-21 pathway
blockade.
Methods Arthritis was induced in DBA/1 male mice with bovine
type II collagen. Animals were treated with either soluble
mIL-21R-Fc, which neutralizes murine IL-21 bioactivity, with
TNFRII-Fc or with control IgG. Spleens from each group of treated
mice were cultured in vitro with collagen and assayed for cytokine
secretion. Cytokines and anticollagen-specific IgG levels were also
measured in the serum by ELISA. Cytokine mRNA levels in the
paws were evaluated by quantitative PCR analysis.
Results Treatment of mice with IL-21R-Fc or TNFRII-Fc reduced
clinical and histological signs of collagen-induced arthritis. IL-6
mRNA in paws and serum IL-6 levels were decreased after IL-21R-
Fc treatment. IFNγ mRNA was increased in paws of IL-21R-Fc-
treated mice. Collagen-specific spleen cell responses from IL-21R-
Fc-treated mice exhibited increased IFNγ and IL-2, and reduced IL-
6 and IL-17 levels. Serum levels of total IgG1 were also reduced in
response to IL-21R-Fc treatment.
Conclusion These data demonstrate a role for IL-21 in the
modulation of collagen-specific T-cell responses and the pathology
of arthritis, supporting a rationale for blockade of the IL-21 pathway
in rheumatoid arthritis.
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Background TNFα is a key cytokine in rheumatoid arthritis (RA)
physiopathology. We recently demonstrated that a new cationic
liposome formulation allowed intravenous delivery of a small
interfering RNA (siRNA) targeting TNFα and efficiently restoring
the immunological balance in an experiment model of RA. Since
30% of patients do not respond to anti-TNF biotherapies, however,
there is a need to develop alternative therapeutic approaches.
Objective Strong association of other proinflammatory cytokines
with the pathogenesis of RA prompted us to investigate which
cytokine other than TNFα could be targeted for therapeutic benefit
using RNA interference.
Methods Two siRNA sequences were designed for IL-1β, IL-6 and
IL-18 proinflammatory cytokines, and their efficacy and specificity
were validated in vitro on J774.1 mouse macrophage cells,
measuring both mRNA and protein levels following a lipopoly-
saccharide challenge. For in vivo administration, siRNAs were
formulated as lipoplexes with the RPR209120/DOPE liposome
and a carrier DNA, and were injected intravenously in DBA/1 mice
having collagen-induced arthritis. The clinical course of the disease
was assessed by paw thickness over time, and radiological and
histological scores were obtained at euthanasia. The cytokine
profiles were measured by ELISA in sera and knee-conditioned
media. The immunological balance was assessed using antitype II
collagen assays. The distribution of siRNAs was evaluated by
fluorometry in GFP transgenic mice over time after anti-GFP siRNA
lipoplex injections.
Results The designed siRNA sequences silenced 70–75% of the
lipopolysaccharide-induced IL-1β, IL-6 and IL-18 mRNA expression
in macrophages compared with a control siRNA. Each siRNA
affected the targeted cytokine specifically, without modifying other
proinflammatory cytokine mRNAs. In the collagen-induced arthritis
model, weekly injections of siRNA lipoplexes significantly reduced
the incidence and severity of arthritis, abrogating joint swelling, and
destruction of cartilage and bone, in both preventive and curative
settings. The most striking therapeutic effect was observed whenS2
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combining the three siRNAs targeting IL-1β/IL-6/IL-18 at once.
Such tritherapy was associated with downregulation of both
inflammatory and autoimmune components of the disease, and
overall parameters were improved compared with the TNFα siRNA
lipoplex-based treatment. The siRNA formulation was widely
distributed, delivering the siRNA to several organs with a strong
efficacy in the liver and spleen.
Conclusion Tritherapy targeting IL-1β/IL-6/IL-18 seems highly
effective to reduce all pathological features of RA including
inflammation, joint destruction and Th1 response. These data show
that cytokines other than TNFα can be targeted to improve
symptoms of RA and reveal novel potential drug development
targets. The systemic administration of anticytokine siRNA cock-
tails as a lipoplex could represent a novel and promising anti-
inflammatory alternative therapy in RA.
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An integrative genomics strategy for the identification of
collagen-induced arthritis susceptibility genes
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Murine collagen-induced arthritis (CIA) is a chronic inflammatory
disease bearing all the hallmarks of rheumatoid arthritis. CIA has
been widely used to study the etiology, pathogenesis and new
therapeutic approaches of rheumatoid arthritis. Previous studies
have identified multiple quantitative trait loci (QTL) controlling
different aspects of disease pathogenesis. However, progress in
identifying the new susceptibility genes outside the MHC locus
has been slow. With the advent of new global methods for genetic
analysis such as large-scale sequencing, gene expression profiling,
combined with classical linkage analysis, congenic and physical
and in silico fine mapping, progress is considerably accelerating.
Here we present preliminary data using an integrative genomics
strategy to identify new putative susceptibility genes contributing
to the pathogenesis of CIA.
The strategy is based on integrating a genome scan to identify
QTLs linked to clinical disease phenotypes and subtraits in a cross
between the CIA-susceptible DBA1/J and resistant FVB/NJ mouse
strains. Additionally, gene expression profiling in target tissues and
immune cells in parental strains and their F2 progeny is performed.
Numerous classical QTL and expression QTL were identified.
Master QTLs/expression QTLs controlling basic disease traits and
subtraits were selected for further analysis using in silico tools; for
example, haplotype sharing analysis, interspecies synteny analysis,
congenic mapping, and pathway construction.
So far we have confirmed C5 as a putative susceptibility gene for
the Cia2 locus on chromosome 2. We also identified the mito-
chondrial ATP8 as a novel susceptibility gene. We are also
pursuing three additional QTLs on chromosomes 1, 5, 18 controll-
ing leukocyte–endothelial cell adhesion, anticollagen antibody
production and arthritis severity. Functional analysis of candidate
genes for those loci is underway.
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Introduction Rheumatoid arthritis is a chronic inflammatory disorder
that primarily affects the joints and results in the destruction of
cartilage and subchondral bone by the inflamed synovium.
Investigating the time course of cartilage destruction is of
importance to better understand whether structural damage is
reversible and when therapeutic intervention may be most effective.
Methods To study the time course and mechanisms of
inflammatory destruction of articular cartilage, we used the human
TNFα transgenic (hTNFtg) mouse model of rheumatoid arthritis.
hTNFtg mice were sacrificed from weeks 2 to 14 in 2-week
intervals, and sections of the hind paws were analyzed for
histopathological changes. Specifically, the cartilage area and
thickness were determined by histomorphometry, and proteo-
glycan loss was assessed by toluidin-blue staining. Inflammation
was quantified by measuring the area of hyperplastic synovial
tissue. The length of adhesion zones between pannus and cartilage
were taken as measures for synovial attachment. To study the
effects of proteoglycan loss on the attachment of synoviocytes in
vitro, synovial fibroblasts were seeded onto isolated and IL-1-
treated (2 ng/ml and 10 ng/ml, 24 hours) murine femoral heads,
and the attachment was quantified by light microscopy.
Results In hTNFtg mice, synovial inflammation increased over time
(0.025 mm2 at week 2 versus 0.65 mm2 at week 14; P < 0.05),
with the most prominent increase between weeks 4 and 6
(0.029 mm2  and 0.78 mm2, respectively; P < 0.05). Loss of
cartilage was seen only between weeks 2 and 4. After week 4, the
cartilage area and thickness remained stable, arguing for a
dissociation between cartilage degradation and pannus formation.
As seen in toluidin-blue staining, a loss of proteoglycans occurred
over time, which started at week 4 and peaked at week 8. There
was a prominent attachment of pannus tissue to articular cartilage.
Attachment started after week 4, peaked at week 10 and showed
a decrease thereafter. This observation was supported by in vitro
attachment data showing that early moderate loss of proteoglycans
(as induced by 1 ng/ml IL-1) strongly enhanced attachment of
synovial fibroblasts while an almost complete loss of proteoglycans
(as induced by 10 ng/ml IL-1) did not facilitate fibroblast attachment.
P5
Histidine deficiency does not protect against aggrecan-induced
arthritis
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Increased numbers of mast cells are found in the synovial tissues
and fluids of patients with rheumatoid arthritis, and at sites ofS3
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cartilage erosion. Mast cell activation has been reported for a
significant proportion of rheumatoid specimens. Because the mast
cell contains potent mediators, including histamine, its potential
contributions to the processes of inflammation and matrix
degradation have recently become evident; thereafter, we
investigated the potential protective effect of histamine deficiency
against aggrecan-induced arthritis. To study the role of histamine in
rheumatoid arthritis we investigated cartilage proteoglycan
(aggrecan)-induced arthritis in histidine decarboxylase knockout
(HDC-KO) mice, with complete lack of endogenously produced
histamine. Aggrecan-induced arthritis was similar in HDC-KO and
wild-type (WT) mice. Arthritis was even more severe in HDC-KO
mice than in the WT animals 10 weeks following the immunization
with aggrecan (arthritis score 1.2 ± 1.5 and 0 ± 0, respectively;
P = 0.01). At later time points, arthritis scores were similar in both
HDC-KO and WT mice. Since T-lymphocyte dysfunction has an
important role in the pathogenesis of rheumatoid arthritis, next we
investigated T-cell signal transduction and cytokine production in
HDC-KO and WT mice. In the absence of histamine, elevated INFγ
mRNA and protein levels of splenocytes (P < 0.001 and P = 0.001,
respectively) were associated with a markedly increased (2.5-fold,
P = 0.0009) nitric oxide (NO) production, compared with WT
animals. Furthermore, histamine treatment decreased the NO
production of splenocytes from both WT and HDC-KO mice
(P = 0.001 and P = 0.0004, respectively). NO precursor (Z)-1-[2-
(2-aminoethyl)-N-(2-ammonioethyl) amino]diazen-1-ium-1,2-diolate-
diethylenetriamine (NOC-18) elicited IFNγ production (P = 0.0002),
suggesting the role of NO in regulating IFNγ synthesis. The
cytoplasmic Ca2+ concentration of unstimulated T cells and the T-
cell activation-induced Ca2+ signal were increased in T cells from
the HDC-KO mice (P = 0.02 and P = 0.04, respectively), while the
T-cell activation-induced CD3 internalization was similar in both
HDC-KO and WT animals. Our present data indicate that
histamine deficiency does not protect against aggrecan-induced
arthritis. The Th1 cytokine pattern and increased NO production
may both contribute to the sensitivity of HDC-KO mice to
aggrecan-induced arthritis. Furthermore, our data indicate that
histamine, in addition to its direct effects on T-lymphocyte function,
regulates cytokine production and T-cell signal transduction
through regulating NO production.
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Mast cell-deficient W/Wv mice are resistant to K/BxN serum transfer
arthritis, and this resistance may be overcome by engraftment with
mast cells. However, the pathways by which mast cells participate in
arthritis remain unknown. Using a candidate mediator approach, we
explored IL-1 as a potentially key mediator by which mast cells
promote arthritis. As expected, IL-1α/β-deficient mice were
completely resistant to arthritis. Short-term administration of
exogenous IL-1 restored an attenuated arthritis course in these
animals, consistent with an ongoing requirement for IL-1. Surprisingly,
deficient W/Wv mice treated with IL-1 at disease induction displayed
a full normal course of arthritis, demonstrating that exogenous IL-1
can bypass the need for mast cells. TNF proved unable to exert a
similar effect. We therefore engrafted IL-1–/– bone marrow-derived
mast cells (BMMC) into W/Wv animals and found that these animals
displayed resistance to arthritis equivalent to nonengrafted W/Wv
mice, consistent with an obligate role for IL-1 of mast cell origin.
Exploring further the mechanisms by which mast cells may become
activated in this IgG1-driven model, we found that BMMC stimulated
in vitro via FcγRIII elaborated IL-1, while BMMC lacking this receptor
were unable to mediate arthritis upon engraftment into W/Wv
recipients. While BMMC engrafted into W/Wv animals
disproportionately populate the spleen, we excluded a contribution
from this aphysiologic mast cell population via splenectomy and by
documenting that systemic levels of IL-1 were not detectable during
arthritis initiation in engrafted animals. We conclude that mast cells
local to the joint and activated via FcγRIII promote K/BxN serum
transfer arthritis by production of IL-1, an activity that appears
delimited to the initiation of disease (the ‘jump start’).
Acknowledgements  This work was supported by grant K08
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The Mer receptor tyrosine kinase mediates apoptotic cell phago-
cytosis and modulates macrophage cytokine production. Mer
knockout mice (Mer-KO) have defective clearance of apoptotic
debris and develop systemic lupus erythematosus-like autoimmune
disease. Because of their spontaneous autoimmune propensity, we
wondered whether Mer-KO mice (backcrossed 10 generations
onto C57BL/6) might be particularly susceptible to the systemic
lupus erythematosus-like autoimmunity induced by chronic graft-
versus-host disease (GVHD). Using the well-established cGVH
model (bm12→B6 mice), we were surprised to observe that the
Mer-KO mice were protected from the development of GVHD.
Mer-KO recipients of bm12 spleen cells failed to develop
detectable anti-dsDNA and antichromatin autoantibodies, while the
B6 hosts produced significant amounts of these antibodies that
peaked at week 2. Slightly increased levels of rheumatoid factor
were found in Mer-KO mice, although much lower than B6 control
hosts. Mer-KO mice did not develop splenomegaly. The lack of
autoantibody formation was not due to an absence of alloreactivity,
because spleen cells from bm12 mice proliferated equally in
response to irradiated wild-type and Mer-KO irradiated spleen
cells. GVHD developed normally in F1 (Mer-KO x B6) hosts given
bm12 donor cells, thus indicating that the failure to develop GVHD
was not due to mer-KO-derived minor MHC genes. These findings
indicate a hitherto unrecognized requirement for Mer in the genesis
of alloreactivity-induced autoimmunity. Future experiments will
determine whether this reflects the role of this kinase in recognition
and phagocytosis of apoptotic cells, its function in regulating
cytokine production, or perhaps a new function in the immune
response.S4
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IL-21 promotes plasma cell (PC) differentiation while BAFF
promotes B-cell survival. Here, we report that IL-21 synergizes with
BAFF to elicit BLIMP-1 induction, PC differentiation and IgG
production from a novel population of human splenic memory B
cells. These human marginal zone analogue B cells are exquisitely
sensitive to IL-21 and BAFF in the absence of further co-
stimulation. The ability of IgG+ marginal zone analogue to respond
specifically and exclusively to IL-21 and BAFF demonstrates that
they are uniquely poised to respond to antigen-independent
signals and differentiate into IgG-producing PC, thereby
replenishing serologic memory. Importantly, peripheral blood B
cells from a portion of patients with systemic lupus erythematosus
and rheumatoid arthritis were highly responsive to stimulation with
IL-21 and BAFF. These data suggest that IL-21 and BAFF may be
capable of inducing PC differentiation from memory B cells with
autoreactive specificities and thereby contribute to autoimmunity.
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Introduction IL-33 (or IL-1F11) was recently identified as a ligand
for the previously orphaned IL-1 family receptor T1/ST2. IL-33
belongs to the IL-1 family of cytokines and upon binding to T1/ST2
induces intracellular signals similar to those of IL-1. Previous
studies have established that IL-33 and T1/ST2 exert key functions
in Th2 responses. Mast cells are known to express T1/ST2.
Besides their well-known function in allergy and host defense, mast
cells have recently been shown to play an important role in
experimental models of arthritis.
Objective To examine the effect of IL-33 on P815 murine masto-
cytoma cells and primary mouse bone marrow-derived mast cells
(BMMC).
Results IL-33 dose-dependently and time-dependently stimulated
IL-6 secretion by P815 mastocytoma cells and BMMC. Both cell
types express T1/ST2 as assessed by RT-PCR and FACS
analysis. This effect was dependent on T1/ST2 binding. The
addition of ST2-Fc on BMMC inhibited the stimulatory effect of
IL-33, whereas etanercept had no effect. IL-1RAcP-Fc alone or in
combination with ST2-Fc inhibited the effect of IL-33, indicating
that IL-33 binds to these soluble receptors. In addition, IL-33 also
induced IL-1β, TNFα, MCP-1, and PGD2 production in BMMC. By
the RNase protection assay, we demonstrated that IL-33 increased
IL-6 and IL-1β? mRNA expression. These effects of IL-33 appeared
to occur independently of mast cell degranulation.
Conclusion The results of this study show for the first time that
IL-33, a novel member of the IL-1 family of cytokines, stimulates the
production of proinflammatory mediators by mast cells in addition
to its effect on Th2 responses. These findings open new perspec-
tives for the treatment of inflammatory diseases by targeting IL-33.
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Background Dendritic cells (DC) can be alternatively activated to
induce tolerogenic DC, making them a promising therapy for auto-
immunity. Because naïve and memory T cells have different
requirements for tolerisation, we tested the modulatory activity of
tolerogenic DC on both subsets of T cells.
Methods Human monocyte-derived DC were matured with
lipopolysaccharide (LPS-DC) or treated with dexamethasone,
vitamin D3 and lipopolysaccharide (LPS-DexD3 DC) to obtain
tolerogenic DC. DC were cocultured with allogeneic naïve or
memory CD4+ T cells. Primed T cells were rested and restimulated
with LPS-DC or CD3/CD28 beads.
Results and conclusions LPS-DexD3 DC have reduced
stimulatory capacity for both naïve and memory T cells. However,
restimulation of T cells revealed a distinct difference between naïve
and memory T cells that had been primed by LPS-DexD3 DC. Naïve
T cells did not become anergic but were skewed to a regulatory
phenotype (low IFNγ and high IL-10 production), whereas memory T
cells were rendered hyporesponsive, with low proliferation and
cytokine production. Thus, naïve and memory T cells are differently
regulated by LPS-DexD3 DC. These data have implications for the
use of tolerogenic DC vaccines as immunomodulators.
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Generation of dexamethasone and vitamin D3-treated human
monocyte-derived dendritic cells with tolerogenic properties
Bethan Sayers, Muzlifah Haniffa, Julie Diboll, John Isaacs,
Catharien Hilkens
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Newcastle University, UK
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Human monocyte-derived dendritic cells (DC) treated with
dexamethasone and vitamin D3 (DexVitD3 DC) have tolerogenic
properties and phenotype. DexVitD3 DC induce limited T-cell
proliferation in an allogeneic mixed lymphocyte reaction and inhibit
the T-cell proliferation induced by lipopolysaccharide and/or
cytokine (TNFα/IL-1β) matured DC. Furthermore, T cells primed
with DexVitD3 DC proliferate in response to restimulation with a
distinct cytokine profile including significantly reduced production
of IFNγ. DexVitD3 DC have characteristically low expression of the
costimulatory molecules CD80/83/86 with high HLA-DR. Upon
stimulation with lipopolysaccharide, DexVitD3 DC maintain their
surface phenotype and produce large quantities of IL-10. We are
currently characterising the cytokine profiles of DexVitD3 DC and
the T cells they prime, as well as investigating whether these T
cells have regulatory properties.
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Cellular therapies are being explored as treatment for autoimmune
diseases including rheumatoid arthritis. DexVitD3 DC have
potential for future use in this field as well as being a useful tool to
elucidate mechanisms of immune regulation.
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The antigens that trigger the pathogenic immune response in
rheumatoid arthritis remain unknown. Until recently it was assumed
that joint-specific antigens were the targets of arthritogenic T
lymphocytes and B lymphocytes in rheumatoid arthritis.
Consequently, murine models of arthritis are induced by
immunization with either joint-specific antigens such as type II
collagen or microbial products such as streptococcal cell wall. In
the K/BxN T-cell receptor transgenic mouse model, arthritis is
caused by a systemic autoimmune response to the ubiquitously
expressed glycolytic enzyme glucose-6-phosphate isomerase
(G6PI). More recently it was shown that G6PI immunization
induces severe symmetrical peripheral polyarthritis in genetically
unaltered DBA/I or SJL mice [1,2]. T cells are indispensable for
both the induction and the effector phase of G6PI-induced arthritis.
Arthritis is cured by depletion of CD4 cells. In contrast, antibodies
and FcγR effector cells are necessary but not sufficient for G6PI-
induced arthritis in genetically unaltered mice [1]. Both the
induction and effector phase of arthritis induced by a systemic
autoimmune response can be dissected and preventive and
therapeutic strategies evaluated in this model.
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Background Eicosanoids are arachidonic acid-derived mediators
that play a key role in the regulation of inflammatory response.
5-Lipoxygenase (5-LOX)-derived leukotrienes are considered pro-
inflammatory while 15-lipoxygenase (15-LOX)-derived products
such as 15-hydroxyeicosatetraenoic acid (15-HETE) and lipoxins
inhibit proinflammatory mediators including leukotrienes, and
actively participate in the resolution of inflammation. It has been
demonstrated that a temporal switch of arachidonic acid
metabolism from predominant 5-LOX-derived to 15-LOX-derived
products is crucial for the resolution of inflammation. We have
recently shown that there is an imbalance between proinflam-
matory leukotrienes and anti-inflammatory lipoxins in the lungs of
patients with systemic sclerosis (SSc)-related interstitial lung
disease, which may favour chronic inflammation and fibrosis [1,2].
Objective To further investigate the role of eicosanoids in the
pathogenesis of SSc through evaluation of: (1) the basal profile of
eicosanoid synthesis, and (2) the pattern of eicosanoid
biosynthesis in response to proinflammatory stimuli by peripheral
blood mononuclear cells (PBMC) from patients with SSc in
comparison with healthy people.
Methods Mononuclear cells were isolated from peripheral blood
using density gradient centrifugation on Lymphoprep and cultured
in fetal calf serum-supplemented RPMI medium at 37°C under 5%
CO2. Ionophore-stimulated production of 5-LOX-derived leuko-
triene E4 (LTE4) and 15-LOX-derived 15-HETE was evaluated by
means of enzyme immunoassay at predefined time points in basal
conditions (without stimuli) as well as in response to TNFα. Ten
patients with SSc (five diffuse and five limited cutaneous SSc) as
well as five healthy controls were studied.
Results There were no significant differences in the basal
production of LTE4 or 15-HETE between SSc patients and healthy
controls. TNFα induced sequential changes in the production of
eicosanoids, with an early (within 1 hour) increase in LTE4
followed by a delayed increase in 15-HETE in both SSc patients
and healthy controls. PBMC from SSc patients responded to
TNFα with significantly higher production of LTE4 in comparison
with healthy controls (P < 0.05 at 1 hour), while there were no
significant differences in TNFα-induced production of 15-HETE
between SSc patients and controls.
Conclusions These preliminary results of our study indicate that
the TNFα-induced eicosanoid synthesis is altered in PBMC from
patients with SSc. Increased production of proinflammatory
leukotrienes may contribute to the pathogenesis of SSc.
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Somatic hypermutation (SHM) is initiated in germinal center (GC)
B cells expressing high levels of activation-induced cytidine
deaminase (AID), which targets WRC (W = A/T, R = A/G) motifs
generating a uracil:guanidine mismatch. During SHM, 73% of the
mutations are attributed to AID and error-prone polymerase eta
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(POLη). To characterize the nature of other mutations, 316
genomic nonproductive V(D)J rearrangements amplified and
sequenced from three AID–/– patients were analyzed. The mutation
frequency was 20-fold less than normals (0.09% versus 2%) but
~5 x 104-fold more than non-B cells. Reduced RGY (6% versus
27%) and WRC (6% versus 15%) motif mutations and decreased
replacements in complementarity determining regions were
attributed to the lack of AID. Reduced WA motif mutations (12%
versus 23%) suggested POLη activity was decreased. Prominent
G>C and A>T biases suggested that mutation and repair
mechanisms occurred preferentially on one DNA strand. A high
percentage of the mutations were G substitutions on the sense
strand (43% versus 29% in normals), reflecting C mutational
targeting on the opposite strand. These were primarily G to A
transitions, suggesting that UNG activity was reduced even though
UNG is upregulated in normal GC B cells and large GCs occur in
AID–/– patients. The mutation pattern suggests that AID-
independent C substitutions contribute a small proportion of SHM
but lack the targeting provided by AID. Finally, a low level of SHM
clearly can develop in the absence of AID; however, this
mechanism is inefficient at altering the binding capacity of immuno-
globulin heavy chain genes.
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Background We previously demonstrated in minor salivary glands
of patients with Sjogren’s syndrome (SS-mSGs) that a true pheno-
menon of ectopic lymphoneogenesis takes places, with the
formation of germinal centres (GCs), in association with the
ectopic expression of the lymphoid chemokines (CKs) CXCL13
and CCL21. In Sjogren’s syndrome major salivary glands (SS-
MSGs) these structures are known to support clonal immuno-
globulin heavy chain gene rearrangements and somatic hyper-
mutation, favouring expansion and selection of autoreactive B-cell
clones, clonally related to lymphomatous B-cell clones (responsible
for lymphoma development in Sjogren’s syndrome (SS)). The
involvement of lymphoid CKs and CXCL12 in the development of
lymphoid malignancies has been demonstrated. At present,
however, no data on the expression of these CKs nor their cellular
source within SS-MSGs and mucosal-associated lymphoid tissue
lymphomas (MALT-Ls) from patients with SS have been described.
Objective To assess the specific contribution of lymphoid CKs in
the organization of lymphoid proliferation within SS-MSGs and SS-
MALT-Ls.
Methods We studied 12 SS-mSGs, four SS-MSGs with lympho-
epithelial lesion and 20 SS-MSGs with non-Hodgkin B-cell MALT-
Ls. In order to define the histological organization of the lymphoid
infiltrate (reactive versus malignant areas) and identify the B-cell
subpopulations infiltrating the glands, immunohistochemistry was
carried out for cellular (CD21, bcl-2, bcl-6, IgD, CD20, CD3,
CD68) and vascular markers (CD31, PNAd). On sequential
sections, digital images for CXCL13, CCL21 and CXCL12 were
analysed by thresholding positive staining in detected areas of
interest. Digital image analysis estimated CK’s volume fraction
areas as a ratio between CXCL13, CCL21 and CXCL12 positive
areas over malignant or reactive areas. CK’s producing cells were
identified by double staining on sequential sections. Mononuclear
cells were isolated from two SS-MALT-L parotids following
enzymatic digestion and stained for CD19, CD38, CD27, CD24,
IgM, IgD, CD10, CD5, CD3, CD4, CD69, CD45RO, CXCR5,
CXCR4 and CCR7. Finally, mRNA from total SS-MSGs and
MALT-Ls and isolated B cells and T cells from MALT-Ls were
analysed by RT-PCR for the transcript levels of CXCL13, CCL21
and CXCL12.
Results Reactive areas, characterized by T-cell/B-cell
segregation, CD20+IgD+bcl-2+ follicular B cells, presence of
follicular dendritic cell networks in GCs and high endothelial
venule formation were detected in 100% of MALT-Ls. A B-cell
population (CD20+IgD–bcl-2+) characterized by nuclear
abnormalities and monocytoid appearance was consistently
observed within the proliferating ducts and identified as the B-cell
malignant component. FACS analysis on isolated MALT-L
mononuclear cells showed B cells in diverse maturative stages
(transitional, mature and memory B cells) and a B-cell population
CD19posIgDlowCD24negCD27low/negCD5negCD10neg not detec-
table in the controls. Ectopic expression of CXCL13 and CCL21
was observed in 100% of SS-MSGs and MALT-Ls. A significant
increase in CXCL13’s volume fraction analysis was observed both
in SS-MSGs and SS-MALT-L reactive areas, as compared with
SS-mSG follicular areas (P < 0.05 and P < 0.05, respectively). A
strong difference in CXCL13 within the MALT-L reactive area
compared with malignant areas was detected (P < 0.001). CCL21
was significantly increased in MALT-Ls compared with both
SS-mSGs and SS-MSGs and was mainly confined to the T-cell
area. CXCL12 was strongly expressed by ductal epithelial cells,
vessels and reactive areas in SS-mSGs, SS-MSGs and MALT-Ls.
Interestingly a significant increase in CXCL12 expression on
MALT-L malignant areas as compared with reactive areas in
SS-mSGs and SS-MSGs was detected (P < 0.01 and P < 0.05).
RT-PCR analysis showed increased CXCL13 and CCL21 level in
SS-MSGs compared with MALT-Ls and SS-mSGs, while strong
upregulation in CXCL12 transcript in MALT-Ls as compared with
SS-mSGs and SS-MSGs was detected.
CXCL13, CCL21 and CXCL12 were detected on CD68+ cells by
immunohistochemistry, while CD20 and CD3, CXCL13 and
CCL21double staining and mRNA analysis on MALT-extracted T
and B lymphocytes showed negligible expression of the two CKs
in MALT-L-extracted lymphocytes. Interestingly we identified strong
CXCL12 expression on CD19+ MALT-L isolated cells both at the
protein and mRNA level and on ductal epithelial cells in close
contact with the malignant B-cell infiltration. In agreement with this
increase, we demonstrated a significant downregulation of CXCR4
on MALT-L-isolated B cells, likely to be the result of CXCR4
internalization upon CXCL12 ligation.
Conclusion In SS-MALT-Ls a strong upregulation of the lymphoid
CKs CXCL13 and CCL21 takes place and is associated with the
organization of the reactive areas involved in the maintenance of
the autoimmune process within the malignancy. These findings
support a contributory role for CXCL13 and CCL21 in the patho-
genesis of MALT lymphomas in SS. These results imply that the
CK/CK– receptor axis is functional in MALT-L malignant cells, and
suggest that the glandular microenvironment, B-cell receptor
signalling upon antigen engagement and autocrine signals from the
same malignant population concur in MALT lymphomagenesis,
triggering local activation of malignant B cells and favouring their
survival and expansion.
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Objective In classic studies on the genetic background of
antibody production, MHC has been shown to act as the most
prominent immune-response gene that controls the magnitude and
the specificity of antibody production. The strongest genetic risk
factor for rheumatoid arthritis (RA), the human MHC, HLA-DRB1
shared epitope (SE) alleles, predisposes for antibodies against
citrullinated proteins (ACPA). ACPA levels are higher in SE-
positive than in SE-negative RA patients. The present study
determines whether SE not only influences the magnitude, but also
the specificity of the ACPA response.
Methods In two independent cohorts of anti-CCP2-positive RA
patients (n= 206 and n= 214 patients, respectively), serum
antibodies against a citrullinated peptide derived from vimentin (cVim)
and antibodies against a citrullinated fibrinogen peptide (cFibr) were
determined by ELISA. HLA-DRB1 genotyping was performed.
Results In the first cohort, SE alleles were significantly associated
with the presence of antibodies against cVim (OR = 4.55, 95%
CI = 1.78–12.9) and not significantly with the presence of anti-
bodies against cFibr (OR = 1.81, 95% CI = 0.78–4.13). These
results were replicated in the second cohort (OR = 4.13, 95%
CI = 1.68–10.3 and OR = 1.08, 95% CI = 0.34–3.23, respectively).
Conclusion In two cohorts of ACPA-positive RA patients, SE
alleles predispose for the development of antibodies against cVim,
and not for the development of antibodies against cFibr. These
data indicate that SE alleles act as ‘classic’ immune-response
genes in the ACPA response, as they influence both the magnitude
and the specificity of this RA-specific antibody response.
Rheumatoid arthritis  
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Recently it was shown that attachment of synovial fibroblasts (SF)
from rheumatoid arthritis patients to laminin-111 (LM-111) induced
an elevated expression of stromelysin-1 (MMP-3). We therefore
investigated the regulation of additional matrix metalloproteinases
(MMPs) and their specific tissue inhibitors of matrix metallo-
proteinases (TIMPs) by attachment to LM-111 in the presence of
transforming growth factor beta (TGFβ). Changes in steady-state
mRNA levels encoding TIMPs and MMPs were investigated by
quantitative RT-PCR. Production of MMPs and cytokines was
monitored by a multiplexed immunoarray or by ELISA. Signal
transduction pathways were studied by immunoblotting. Attach-
ment of SF to LM-111 in the presence of TGFβ induced significant
increases in stromelysin-1 mRNA (12.35-fold, P < 0.001) and
protein (mean 62 ng/ml, sixfold, P < 0.008). Expression of
stromelysin-2 (MMP-10) mRNA (11.68-fold, P < 0.05) and protein
(54 ng/ml, 20-fold, P ≥ 0.02) was significantly activated as well. All
other TIMPs and MMPs investigated failed to show this LM-111-
facilitated TGFβ response. Induction of stromelysin-1 and
stromelysin-2 was associated with the activation of transcription
factors c-fos and Egr-1, but phosphorylation of NF-κB was not
observed. Further, LM-111-activated and TGFβ-activated SF failed
to produce remarkable amounts of IL-1β or TNFα. We conclude
that costimulation of synovial fibroblasts by LM-111 together with
TGFβ suffices to induce significant expression of MMP-3 and
MMP-10 by SF and that this induction is independent of phos-
phorylation of NF-κB.
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Background Single nucleotide polymorphisms (SNPs) of the TNF
gene at positions –238 and –308 have earlier been associated
with psoriasis vulgaris and psoriatic arthritis (PsA). However, a
strong linkage disequilibrium at the chromosomal region 6p21
renders the interpretation of these findings difficult since also other
risk factors for psoriasis (PSORS1) than SNPs of the TNF gene
have bee mapped to that particular region. Therefore, in this study
several SNPs of the TNF gene and of its neighbouring lymphotoxin
α (LTA) gene were analysed independently and dependently on
carrying the PSORS1 risk allele.
Methods SNPs in the promoter of the TNF gene (–238G/A,
–308G/A, –857C/T, –1031T/C), and one SNP of the LTA gene
(+252A/G), of the TNLFRSF1A gene (+36A/G) and of the
TNLFRSF1B gene (+676T/G), respectively, were genotyped in
375 psoriasis patients, 375 PsA patients, and 376 controls. The
tryptophan–tryptophan–cysteine–cysteine haplotype of the
CCHCR1  gene (CCHCR1*WWCC) was used to estimate the
genetic impact of the PSORS1 risk allele.
Results Whereas an earlier-described association of allele
TNF*–238A with psoriasis could be confirmed, our study revealed
that this association was completely dependent on concomitant
carriage of the PSORS1 risk allele. For PsA, but not psoriasis
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vulgaris without joint manifestations, strong association with the
allele TNF*–857T was detected (OR = 1.956; P value corrected
for multiple testing, Pcorr = 0.0025) also in patients negative for the
PSORS1 risk allele.
Conclusions  Our results indicate genetic differences between
psoriasis vulgaris patients with and without joint manifestation.
While the previously reported association between TNF*–238A
and psoriasis seems to primarily reflect linkage disequilibrium with
PSORS1,  TNF*–857T may represent a risk factor for PsA
independent of PSORS1. A potential pathophysiologic relevance
of the elucidated genetic association is further suggested by
previously reported experimental evidence for a functional impact
of the respective TNF polymorphism on TNFα expression levels.
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Background There are few rheumatologists who now use the
technique of arthroscopy; in most centers, referral is made to an
orthopedic surgeon who specializes in this technique. It has
become clear in recent years that the synovium is the primary site
of inflammation and the major effecter organ in a variety of joint
diseases including rheumatoid arthritis [1]. The present retro-
spective study was primarily carried out to assess the safety of this
procedure in the hands of a rheumatologist and also to assess the
utility of the procedure in various joint diseases.
Objective To evaluate the safety and diagnostic value of medical
arthroscopy performed by a rheumatologist.
Methods Decisions for performing arthroscopy were taken when a
detailed clinical history and relevant rheumatological investigations
failed to arrive at a definite diagnosis. Initial assessment included
detailed clinical history and relevant diagnostic tests for rheumatic
diseases. Routine blood count, bleeding time, clotting time and
biochemical parameters were also determined. After obtaining
written consent, arthroscopies were performed as an outpatient
department procedure using a 4 mm arthroscope with 0° and 30°
viewing. All the procedures of arthroscopy were performed by a
single rheumatologist. Procedures were done in a minor operating
theatre under local anesthesia using strict aseptic precautions.
Xylocaine 2% and bupivacaine 0.5% were used as local anesthetic
agents for skin portal and intraarticular anesthesia, respectively. A
tourniquet was not used during the procedures and the skin portal
was not stitched. Synovial biopsies taken during procedures were
subjected to only histopathological examination. All the procedures
were recorded on a video-cassette.
Results See Tables 1 and 2. None of the patients developed any
complications during the procedure or after 6 months of follow-up.
None of the patients experienced any discomfort during the
procedure except for a mild stretching sensation experienced by
male patients. Females tolerated the procedure better than males.
Conclusion Arthroscopy using a 4 mm scope in the hands of
rheumatologists is a safe daycare procedure. It can be performed
without a tourniquet. The local anesthetic agent bupivacaine
provides an excellent local anesthesia. Females tolerate the
procedure better than males. In a few cases arthroscopy helped in
arriving at a final diagnosis but many patients remained
undiagnosed. Both the rheumatologists and the pathologists
require further experience in this field.
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Background Thickening of the synovial membrane with
proliferation of macrophage-like and fibroblast-like synoviocytes is
observed in affected joints of rheumatoid arthritis (RA) patients, as
well as extensive synovial infiltration of inflammatory cells. TNF
plays a key role in driving the pathogenesis and persistence of RA.
Blockade of TNF, using current biologics, has had profound thera-
peutic effects; nevertheless, between 30% and 40% of RA
patients do not respond to this treatment. The mechanisms of
response and nonresponse to biologic therapy remain unclear. p38
MAPK is present in the rheumatoid synovium and thought to play a
role in the pathogenesis of RA, suggested by evidence that p38 is
required for TNF-induced inflammatory processes. There are four
p38 MAPK isoforms, α, β, γ and δ, which are found in varying levels
in inflammatory cells. Although most research has to date focused
on p38α, it has been demonstrated in the synovium that the
functional protein produced from the L1 retrotransposable element
can specifically induce p38δ. This suggests a possible second
p38-mediated pathway of joint destruction in RA that may not be
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Table 1 (abstract P19)
Patient characteristics
Total number of patients 50
Number of males 39
Number of females 11
Mean age of patients (years) 35.5
Table 2 (abstract P19)
Postarthroscopy diagnosis
Polyarticular gout 3
Monoarticular gout 2
Oligoarticular gout 3
Tubercular monoarthritis 3
Villonodular synovitis 1
Synovial chondromatosis 1
Histoplasmosis 1
Osteoarthritis 1
Septic arthritis 1
Rheumatoid arthritis 5
Nonspecific chronic synovitis 29S9
blocked by anti-TNF therapy. This study aimed to correlate the
expression of p38δ in the rheumatoid synovium with clinical
response and nonresponse to the anti-TNF biologic, infliximab
(Remicade).
Methods We examined the expression of p38 MAPK isoforms (α
and  δ) pre and post infliximab therapy in the synovium of RA
patients, to compare clinical response with nonresponse. All
patients entered into this study have failed at least two disease-
modifying drugs, and fulfil the revised 1987 ACR criteria for RA.
The effect of TNF blockade in five responders and three non-
responders on the p38 MAPK α and  δ isotypes was studied;
expression and activation (phospho-p38) in synovial biopsies of
responders and nonresponders was measured by immuno-
histochemistry using a semiquantitative scoring system, at baseline
and approximately week 16 of therapy. A therapeutic effect was
determined by patients achieving an ACR20 response at week 14,
and the Wilcoxon signed rank test was performed to assess
significance of changes in expression levels post treatment.
Results In responders, p38α, p38δ and phospho-p38 expression
were all significantly decreased post infliximab treatment in the
synovial sublining layer (P < 0.05). A similar trend was seen in the
synovial lining layer of responders, with a decrease in expression of
p38α and p38δ and phospho-p38 post infliximab treatment in four
of five responders, although these results did not reach statistical
significance. p38δ and phospho-p38 in the sublining layer and
phospho-p38 in the lining layer increased, or remained high, in all
three nonresponders tested, and this tendency was the opposite to
that seen in the responders.
Conclusion In the RA synovium, expression and activation of p38α
and p38δ in the sublining layer correlated with response, and
increased p38δ expression and activation was associated with
nonresponse. A flow cytometric-based investigation of p38 isoform
expression/activation in peripheral blood mononuclear cells has
been initiated.
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Cadherin-11 is a homophilic adhesion molecule that is expressed
on fibroblast-like synoviocytes. Cadherins mediate tissue morpho-
genesis and architecture. Cadherin cell adhesion contacts are
actively remodeled and impact cell movement and migration over
other cells. To determine the molecular mechanisms that contri-
bute to cadherin-11-dependent cell migration, we generated
cadherin-11 mutants. We found that expression of a mutant
cadherin-11 lacking the cytoplasmic juxtamembrane domain (JMD)
diminished the turnover of α-catenin at adherens junctions as
measured by fluorescence recovery after photobleaching. This
resulted in markedly diminished cell intercalation into monolayers
reflecting reduced cadherin-11-dependent cell motility on other
cells. Furthermore, the actin cytoskeleton in cadherin-11 ΔJMD
cells revealed a more extensive cortical F-actin ring that correlated
with significantly higher levels of activated Rac1. Together, these
studies implicate the cadherin-11 cytoplasmic JMD as a regulator
of intercellular motility and cellular rearrangement in multicellular
clusters and provide insight into a critical pathway that determines
the behavior of fibroblast-like synoviocytes in arthritis, especially
rheumatoid arthritis.
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Cadherin adhesion molecules, structurally typified by their
immunoglobulin-like extracellular (cadherin) domains rigidified as
an extended chain by interdomain calcium binding, mediate cellular
adhesion by binding a cadherin of the same type on an adjacent
cell (homophilic adhesion). During embryonic development,
cadherins provide a basis for cell sorting, aggregation and
resultant tissue morphogenesis and they are thought to contribute
to tissue maintenance postnatally. In tumors, cadherins have been
implicated in tissue extension, migration and invasion. Knowing
these processes are active in the synovium both at baseline and in
the context of the hyperplastic and invasive synovial tissue in
inflammatory arthritis, we hypothesized that a cadherin may play a
role in regulating this tissue behavior. Using mouse models, we
demonstrate that synovial tissue fibroblasts express cadherin-11.
We find that cadherin-11 null mice display a hypoplastic synovial
lining and display attenuated arthritic responses to K/BxN serum
transfer arthritis. Moreover, we find a remarkable decrease in
synovial pannus invasion into cartilage. These observations reveal a
role for cadherin-11 in the molecular regulation of the organized
behavior of the synovial fibroblast both in health and disease.
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Background Accumulating data indicate that bone marrow (BM) in
rheumatoid arthritis (RA) patients participates in the pathogenesis
of RA as a site of proinflammatory cytokine overproduction,
lymphocyte homing and cell activation. IL-1b, IL-6, TNFα and IL-15
are among the proinflammatory cytokines elevated in RA in
comparison with osteoarthritis (OA) patient BM. At present, it is
unclear why the RA BM microenvironment produces more
proinflammatory cytokines than OA BM. One possibility is that, in
addition to physiological production, exogenous and/or endo-
genous factors further enhance innate immune responses in RA
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BM. Importantly, our recent data indicate that RA BM-derived B
cells express functional Toll-like receptor 9 (TLR9), and therefore
could respond to TLR9 agonist stimulation.
Objectives To test the effects of TLR9 agonists (oligodeoxy-
nucleotides containing unmethylated CpG sequences (CpG-ODN))
on RA BM-derived B cells, and to estimate the presence of
bacterial DNA in BM from RA and OA patients.
Methods BM samples, obtained from RA patients during joint
replacement surgery, served for bone marrow mononuclear cell
isolation. Mature (CD20+) B cells were next purified from bone
marrow mononuclear cells using a magnetic cell separation
technique (MACS) and cultured in vitro in the presence of
agonistic CpG-ODN or control GpC-ODN alone or with addition of
IL-15. mRNA was isolated from purified B cells using Trizol and
served as the template for RT-PCR analysis. The presence of
bacterial DNA in BM plasma and bone marrow mononuclear cells
was evaluated by DNA extraction and PCR amplification using
primers specific for eubacterial 16S-ribosomal RNA. Flow
cytometry was applied to assess the expression of intracellular
proteins (TLR9 and proliferation marker Ki-67) and surface
activation markers (CD86, CD54) on B lymphocytes. B-cell
populations were distinguished according to CD19, CD20, CD27
and CD138 molecule expression. Specific ELISAs were used to
measure TNFα and IL-6 in supernatants from cultured cells.
Results We found that BM-derived B lymphocytes isolated from
RA patients express TLR9 at the mRNA and protein levels.
Importantly, these TLR9 are functional. Stimulation of B cells by
CpG-ODN, but not control GpC-ODN, in a dose-dependent
manner enhanced expression of activation markers (CD86 and
CD54), and stimulated IL-6 and TNFα secretion and cell prolifera-
tion in vitro. The specificity of CpG-ODN-triggered stimulation was
confirmed in blocking experiments where cells cultured in the
presence of chloroquine, a known inhibitor of TLR9 signaling, failed
to respond to CpG-ODN. Moreover, in the presence of IL-15,
stimulatory activities of TLR9 agonists were further enhanced.
CpG-ODN, but not IL-15 alone, trigger differentiation of sorted B
cells into CD19+CD20+CD27high cells. Simultaneous addition of
CpG-ODN and IL-15 promoted further differentiation of
CD19+CD20+CD27high cells toward plasma cells, as judged by
upregulation of CD138 and downregulation of CD19 and CD20
expression. Finally, the presence of highly conserved regions of the
eubacterial 16S-ribosomal RNA gene in samples of BM from RA
patients was found at significantly higher frequency when compared
with OA patients.
Conclusion Our data indicate that BM of RA patients may
represent an important secondary lymphoid organ that, especially
during ongoing infection with the presence of bacterial DNA in
blood and ultimately in BM, actively participates in the patho-
genesis of RA.
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A 49-year-old female was diagnosed with polyarticular, rheumatoid
factor-positive juvenile idiopathic arthritis at the age of 15.
Advanced destruction required bilateral knee joint replacement
8 years later. Persistent inflammatory activity led to rituximab treat-
ment (1,000 mg on days 1 and 15) in an advanced disease stage.
Peripheral blood analyses showed immediate B-cell depletion.
Synovial tissue histology 8 months later in the early reconstitution
phase revealed scattered follicular-like infiltrates including CD20+
B cells. Flow cytometry of homogenized tissue showed CD19+ B
cells predominantly representing an IgD–CD27+ class switched
memory phenotype, which was contrasted by >90% IgD+CD27–
peripheral blood B cells. This observation, which indicates either
local persistence or early B-cell repopulation and a composition of
synovial B cells discordant to peripheral blood, could have an
impact on the future development of monitoring strategies after
rituximab treatment in arthritis.
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Recent studies have identified CD74, the cell surface form of the
class II-associated invariant chain, as a binding site for the cytokine
macrophage migration inhibitory factor (MIF). MIF is implicated in
the pathogenesis of rheumatoid arthritis and systemic lupus
erythematosus, but a functional relationship between MIF and
CD74 in inflammation has not been demonstrated. We used
CD74–/– mice to examine the role of this molecule in cellular and in
vivo inflammatory responses, using innate immune response-
dependent models to avoid confounding by the role of MHC Ii in
adaptive immunity.
MIF has a demonstrated role in macrophage responses to
endotoxin. LPS induced IL-1, IL-6, TNF and MIF release from WT
bone-marrow macrophages. Bone-marrow macrophages lacking
CD74 released significantly lower amounts of IL-1 and IL-6, but no
difference in TNF release was evident. LPS-induced MIF release by
WT and CD74–/– bone-marrow macrophages was also similar.
Murine K/BxN serum-transfer arthritis is MIF dependent [1], and
also requires the induction of IL-1. Compared with WT mice,
arthritis severity (clinical score) was significantly lower in mice
lacking CD74 (P < 0.05). These data imply but do not demon-
strate a role of CD74 in MIF-dependent inflammatory responses.
To confirm the role of CD74 in responses to MIF in vivo, we
examined a recently described action of MIF – the induction of
leukocyte trafficking [2]. rhMIF was injected into mouse cremaster
tissue and leukocyte–endothelial interactions examined using
intravital microscopy. MIF induced leukocyte adhesion and
emigration in vivo in WT mice. In CD74–/– mice, in contrast, this
response could not be elucidated.
These data demonstrate for the first time the role of CD74 in innate
immune responses and inflammatory arthritis, and demonstrate for
the first time in vivo the requirement for CD74 for the action of MIF.
A functional role for CD74 in MIF responses in inflammation is
strongly supported.
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Experimental and clinical evidence for T-cell involvement in the
pathogenesis of rheumatoid arthritis (RA) is compelling, and points
to a local dysregulation of T-cell function in the inflamed joint. Nitric
oxide (NO) has been shown to regulate T-cell function under
physiological conditions, but overproduction of NO may contribute
to lymphocyte dysfunction in RA. NO has recently been recognized
as a key signaling intermediate for T-cell activation and mitochon-
drial biogenesis. NO is synthesized from L-arginine by NO
synthetases (NOS). Three distinct isoforms of NOS are known,
including neuronal NOS (nNOS), inducible NOS (iNOS), and
endothelial NOS (eNOS) enzymes. We previously detected the
expression of eNOS and nNOS and the absence of iNOS in
human PBL, while during inflammation macrophages and mono-
cytes express iNOS. Systemic lupus erythematosus (SLE) is a
systemic autoimmune disease of unknown origin characterized by
the involvement of multiple organs. Several studies carried out on
patients with both RA and SLE have documented increased
endogenous NO synthesis, but its contribution to T-lymphocyte
mitochondrial biogenesis and T-cell dysregulation is not known.
We investigated the role of NO in T-cell mitochondrial biogenesis
in RA and SLE.
The mitochondrial mass, NO production and cytoplasmic Ca2+
levels were measured by flow cytometry. Mitochondria were
visualized using transmission electron microscope.
T cells from RA patients produce >2.5 times more NO than T cells
from healthy donors (P < 0.001). Unexpectedly, the mitochondrial
mass was found to be similar in RA and control T cells (P = 0.65),
whilst increased NO production was associated with increased
cytoplasmic Ca2+ concentrations in RA T cells (P < 0.001). We
observed that T-cell NO production decreased in most RA patients
following anti-TNF treatment. Although lupus T cells produced
comparable amounts of NO to normal T cells, lupus monocytes
produced twice as much NO as normal monocytes (P = 0.015).
We also observed increased mitochondrial mass (47.7 ± 2.8%;
P = 0.00017) and increased cytoplasmic (38 ± 6.4%; P = 0.0023)
Ca2+ content in T cells from SLE patients when compared with
control donors. Electron microscopy revealed that T cells of lupus
patients contained 8.76 ± 1 mitochondria, while control donors
contained 3.18 ± 0.28 mitochondria per cell (P = 0.0009). In
addition, lupus lymphocytes harbor several-fold enlarged mega-
mitochondria. These data suggest that monocytes are the primary
source of NO in SLE, while T lymphocytes are the primary source
of NO in RA. Although the iNOS pathway is not as rapid as eNOS
or nNOS, it is thought to be capable of generating much larger
quantities of NO (nanomolar range) than the constitutive NOS
isoforms (picomolar range), explaining the differences in T-cell
mitochondrial biogenesis in SLE and RA. Since mitochondria can
take up, store and release Ca2+, increased mitochondrial mass may
account for altered Ca2+ handling in SLE. Furthermore increased
NO production may contribute to T-cell dysfunction in both SLE
and RA.
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We have previously demonstrated reduced circulating levels of
IL-7 in active rheumatoid arthritis (RA) compared with health [1].
Controversy exist as to whether IL-7 correlates or not with
C-reactive protein (CRP) in active disease or with other disease
activity markers. Normal IL-7 levels were, however, found in 50% of
patients in clinical remission and correlated with the recovery of
thymic activity [1]. Patients in clinical remission may represent a
heterogeneous group, and the aim of this work was to identify
predictors of IL-7 recovery in demographic, clinical, imaging and
functional data and to compare them with IL-7 in active disease.
One hundred and six patients deemed to be in clinical remission
were recruited: stable disease for the preceding 6 months,
previous disease duration of at least 12 months, no clinically
significant synovitis, CRP below 15 mg/l for the preceding
6 months. Blood and serum were collected from these patients
(n = 106). Clinical data and imaging data were gathered at the
time of sampling. High-sensitivity ELISA was used for cytokine
analysis, proliferation assays for T-cell function (mitogen, T-cell
receptor stimulation, IL-2, recall antigens); real-time PCR to
quantify T-bet and GATA3 expression, and DNA sequencing was
carried out to investigate two genetic polymorphisms in the IL-7
gene.
Several studies in healthy controls indicate that normal levels of
circulating IL-7 are between 10 and 25 pg/ml. In remission,
circulating levels of IL-7 vary between 2.47 and 23.85 pg/ml.
Recovery of T-cell function was directly related to levels of
circulating IL-7 in vivo (P < 0.001,  R = 0.873 for phytohaemag-
glutinin, R = 0.786 for T-cell receptor stimulation and R = 0.821
for recall antigen). Age and sex had no effect on IL-7. Combining
active (n = 35) and remission patients (n = 106) showed no
indication of a relationship between IL-7 and routine measures of
disease activity (CRP, DAS28, erythrocyte sedimentation rate,
plasma viscosity and joint counts), suggesting that recovery of IL-7
is not an indicator of remission. To confirm this observation, we
used imaging data (MRI and US assessment of hand and wrist) to
address whether subclinical disease could predict lack of IL-7
recovery. Evidence of subclinical synovitis was found in 96% of
patients in remission [2] despite no evidence of clinically significant
synovitis and there was no relationship between IL-7 and imaging
scores. However, we found that levels of IL-7 in remission and the
age of the patient at disease onset correlate (P < 0.001,
R = 0.498, n = 86). A family history of RA and smoking at the time
of onset (both self-reported) were also strongly associated with
lower levels of IL-7 (both P < 0.001, n = 66). We analysed two
polymorphisms in the promoter and enhancer regions of the IL-7
gene. We found no allele frequency difference between RA
patients and healthy controls, remission patients with or without
family history, or in relation to IL-7 levels. Finally we analysed
circulating cytokines known to regulate IL-7 expression, and found
a strong correlation between IL-7 and IFNγ (P < 0.03, R = 0.650,
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n = 10). Since IL-7 is a co-activator of Th1 polarisation, we
analysed the expression of T-bet and found a direct relationship
between the two (P  < 0.01, R = 0.601, n = 15) but not with
GATA3, which is a regulator of Th2 polarisation.
Recent evidence suggests an important role for IL-7 in the
pathogenesis of RA [3]. Our data demonstrate that circulating IL-7
is not an indicator of disease activity. Despite the relationship with
age at onset (genetic anticipation) and the family history associa-
tion, levels of IL-7 in the circulation are apparently not driven by
these two polymorphisms. Our results suggest that Th1 polarisa-
tion and IL-7 are related and that the mechanism by which IL-7 is
recovered in remission may be associated with the recovery of Th1
polarisation.
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Background Recent evidence suggests an important role for IL-7
in the pathogenesis of rheumatoid arthritis (RA) and a therapeutic
potential for IL-7 blockade [1]. IL-7 is produced by synovial stromal
cells (StrC) in RA but is barely detectable in osteoarthritis [2]. Our
published data showed reduced production of IL-7 by bone
marrow (BM) StrC and reduced levels of circulating IL-7 in RA
compared with health [3]. IL-7 was also detected in synovial tissue
in active RA but levels were below detection in clinical remission.
These conflicting observations suggest that the regulation of IL-7
expression is tightly controlled at the level of tissue specificity. To
support this hypothesis, we showed that several cytokines have a
different effect on IL-7 production in BM StrC, epithelial cells from
the liver and gut. This work aims at identifying the factors that
regulate IL-7 production in StrC isolated from synovial tissue of RA
patients.
Results Synovial fluid and tissue biopsy were obtained from RA
(n = 6) and osteoarthritis (n = 4) patients (documented with inflam-
mation scores, visual analogue score) and BM aspirates from
healthy donors (n = 6). Skin fibroblasts were used as negative
control. We quantified IL-7 in freshly isolated StC (using an
advanced cell-sorting strategy [4]) from healthy BM and showed
that IL-7 expression is high. However expression declined rapidly
with tissue culture (20-fold by passage 2), suggesting that
environmental factors are required to sustain IL-7 expression in
vitro. IL-7 expression was threefold lower in expanded StrC from
RA synovial tissue compared with healthy BM; however, levels
were also directly correlated with a visual analogue score of inflam-
mation performed during arthroscopy (ρ = 0.930, P < 0.001).
IL-7 expression is regulated by several cytokines. IFNγ induced IL-7
by ninefold in health but this regulation is lost in RA in direct
relationship with levels of inflammation (ρ = 0.842, P < 0.001). In
contrast, TNFα and IL-1β induced IL-7 by an average of threefold
and 15-fold, respectively, in RA but had no effect on healthy BM
StrC. The effect of these cytokines was again correlated with
exposure to inflammation (ρ = 0.883, P < 0.001 for TNFα and
ρ = 0.964, P < 0.001 for IL-1β). TGFβ1 reduced IL-7 expression in
health (fivefold) but had no effect in RA. Therefore, the promoter of
IL-7 is only sensitive to regulation by other cytokine at low levels of
exposure to inflammation. In contrast, IL-7 expression is maximal at
high levels of inflammation and cannot be further increased by
other cytokines.
Conclusion The expression of IL-7 is tightly controlled in health,
the accessibility of the IL-7 promoter to regulation by other cyto-
kines probably being restricted by tissue specificity. In contrast, in
RA joints this regulation is abrogated in direct relation with
exposure to inflammation. The specific effect of cytokine is
therefore only observed when inflammation is low, suggesting
promiscuity on the promoter of the IL-7 gene. This may be resulting
from an alteration of the IL-7 promoter at the epigenetic level
possibly through the effect of Line 1-mediated hypomethylation of
chromatin [5].
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Background The potential value of autologous mesenchymal stem
cells (MSCs) derived from a patient’s joint is now well recognized
in osteoarthritis (OA) and rheumatoid arthritis (RA) for the repair of
bone and cartilage damage. However, the fact that MSCs have
been directly exposed to inflammation in the joint has not been
given sufficient attention. We have shown recently that chondro-
genesis was qualitatively diminished in MSCs derived from the
synovial fluid of RA patients compared with OA [1]. In this report,
we investigate the effect of the joint microenvironment on MSCs’
repair capability in vitro and the possible molecular mechanism by
which cells become deficient.
Results Synovial tissue was obtained during arthroscopy from 15
patients with RA and OA, fully documented with visual analogue
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scores, which were validated as measure of inflammation locally.
High and low levels of inflammation were observed for both
diseases. We observed an inverse relationship between levels of
inflammation in the joint (VAS) and the chondrogenic potential of
MSCs (R = –0.750, P < 0.01) using an in vitro differentiation assay.
Such a relationship was not observed for bone differentiation.
The induction of two specific transcription factors (TF) is necessary
for differentiation to take place: Sox9 for chondrogenesis and
Runx2 for osteogenesis. We measured the levels of expression of
these TF in MSCs isolated from nine synovial fluids of RA and OA
patients and compared them with MSCs isolated from healthy
bone marrow donors (n = 6) and skin fibroblasts (negative control,
n = 4). Sox9 expression was higher in OA than in bone marrow but
was reduced to negative control levels in RA. Runx2 expression
was reduced in both RA and OA. Sox9 and Runx2 expression was
also investigated in synovial tissue MSCs from six RA patients.
Sox9 and Runx2 expression were inversely correlated with VAS
scores for inflammation (R = –0.737, P < 0.01 and R = –0.843,
P < 0.01, respectively).
To investigate the effect of proinflammatory cytokines on the ability
of MSCs to differentiate we quantified the expression of Sox9 and
Runx2 following treatment with TNFα, TGF-β3, and IFNγ. TGF-β3 is
a trigger of chondrogenesis and accordingly increases the expres-
sion of Sox9 and Runx2 in bone marrow MSCs (n = 4), whereas
TNFα and INFγ reduce the expression of both TF. In RA (n = 6),
TGF-β3 had lost the ability to induce the expression of Sox9 and
Runx2 whereas TNFα and INFγ increased it. The cytokine effects
were all directly correlated with previous exposure to inflammation
(P  < 0.05). Therefore, in vivo the joint ‘milieu’ (which includes
these cytokines and several others) is unlikely to allow the
induction of a differentiation pathway where TF must be expressed
at the right time and amounts and in the right order. Finally, using
tissues collected pre and post biologic treatment, we also
demonstrated that this deficit can be corrected in vivo in a
controlled joint milieu (but so far not in vitro) – raising the hope that
one day cell-based therapies for cartilage repair will be available.
Conclusion Altogether, these data demonstrate that exposure to
inflammation has a profound effect on the ability of MSCs to
respond to differentiation triggers. Our data also suggest that
cytokine(s) are likely to be involved in the acquired deficit in
chondrogenesis in RA. Controlling joint inflammation with anti-TNF
is associated with the downregulation of inflammation-related
parameters (including bone damage [2]) and would therefore be
necessary, but may not be sufficient to allow MSCs to undertake
cartilage repair.
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Background In Northern European Caucasian patients with
rheumatoid arthritis (RA), anticyclic citrullinated peptide (anti-CCP)
antibodies are associated with the HLA-DRB1 shared epitope and
are of diagnostic value. In Greek patients with RA the HLA shared
epitope was reported in a minority of patients.
Methods Using an ELISA (CCP2) kit, we tested anti-CCP
antibodies in serum samples from 155 Greek patients with RA,
178 patients with other rheumatic diseases and 100 blood donors.
We also determined rheumatoid factor (RF) and compared it with
anti-CCP antibodies for the area under the curve (AUC), sensitivity,
specificity and likelihood ratios. In RA patients we assessed the
activity score, and radiographic joint score. Extra-articular manifes-
tations were recorded in an additional 75 RA patients.
Results The sensitivity of anti-CCP antibodies for RA was 63.2%
and the specificity was 95.0%. The respective values of RF were
59.1% and 91.2%. When considered simultaneously, the AUC for
anti-CCP antibodies was 0.90 with a 95% CI of 0.87–0.93 and
the AUC for RF was 0.71 with a 95% CI of 0.64–0.77. The
presence of both antibodies increased specificity to 98.2%. Anti-
CCP antibodies were positive in 34.9% of RF-negative RA
patients. Anti-CCP antibodies exhibited a correlation with the
radiographic joint damage (Spearman correlation coefficient
r = 0.27, P = 0.001). Anti-CCP-positive RA patients had increased
the swollen joint count and serum CRP concentration compared
with anti-CCP-negative RA patients (Mann–Whitney U test, P = 0.01
and P < 0.001, respectively). However, no correlation was found
between anti-CCP antibodies and the DAS28 score (r = 0.13,
P = 0.12). RA patients with high anti-CCP2 antibodies
(>100 IU/ml) were more likely to have extra-articular manifestations.
Conclusion In Greek patients with RA, anti-CCP2 antibodies
exhibit a better diagnostic value than RF. Anti-CCP2 antibodies
show a correlation with joint damage whereas high levels of anti-
CCP2 antibodies are associated with extra-articular manifestations.
Anti-CCP2 antibodies are therefore useful in rheumatology practice.
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Background CD20-directed therapy is well established in
oncology, and was recently demonstrated to be highly effective in
the treatment of rheumatoid arthritis (RA) [1]. Small modular
immunopharmaceutical drugs are smaller than antibodies yet are
capable of utilizing effector functions of antibody-dependent
cellular cytotoxicity, complement-mediated cytotoxicity and apop-
totic signaling. TRU-015 is a small modular immunopharmaceutical
drug candidate that is specific for CD20. TRU-015 has been
demonstrated to effectively deplete B lymphocytes in cynomolgus
monkeys in a dose-dependent manner, and to improve survival in
mouse xenograft tumor models [2,3].
Objectives This phase 1 dose escalation study was performed to
evaluate the safety, pharmacokinetics and pharmacodynamics of
TRU-015 in subjects with RA.
Methods Thirty-seven RA subjects receiving a stable background
of methotrexate were enrolled in eight dosage groups (single
dosages of TRU-015 of 0.015, 0.05, 0.15, 0.5, 1.5, 5, or 15 mg/kg,
or two doses of 15 mg/kg given 1 week apart (30 mg/kg)). Safety
was assessed at baseline, during infusion and at prespecified
intervals after infusion by clinical (adverse events, physical
examination, vital signs) and laboratory parameters. Serum samples
were collected for pharmacokinetic analysis. Pharmacodynamic
response was measured using B-cell counts (CD19+ cells by flow
cytometry) at prespecified timepoints. Subjects were evaluated for
a minimum of 4 weeks and until B-cell recovery.
Results At least four subjects were exposed at each dose level.
TRU-015 was generally well tolerated. No dose-limiting toxicities
were observed, and no serious adverse events have been reported.
Decreases in peripheral B-cell counts were observed in all dose
groups at the first time-point after drug administration (24 hours),
with doses ≥0.5 mg/kg causing depletion of peripheral B cells. The
degree, duration, and recovery of B-cell depletion were dose
dependent. Pharmacokinetic parameters of TRU-015 were
calculated for cohorts receiving 0.5 mg/kg and higher, and are
presented in Table 1. The overall mean half-life of TRU-015 was
295 hours.
Conclusion TRU-015, a novel CD20-directed therapy, was
generally well tolerated and resulted in dose-dependent B-lympho-
cyte depletion. Following intravenous infusion, pharmacokinetic
properties of TRU-015 (area under the curve, maximum
concentration of drug) were approximately dose proportional.
Further evaluation of TRU-015 is warranted for the treatment of
RA, and other autoimmune diseases.
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Background Protein therapeutics directed toward CD20 antigen
on B lymphocytes have been demonstrated to be highly effective in
the treatment of rheumatoid arthritis (RA) [1-3]. Small modular
immunopharmaceutical drugs are single-chain polypeptides that
are smaller than antibodies. TRU-015 is a CD20-directed small
modular immunopharmaceutical drug candidate that effectively
depletes B lymphocytes in cynomolgus monkeys in a dose-depen-
dent manner, and improves survival in mouse xenograft tumor
models [4,5].
Objective Previously, a dose-escalation study in subjects with RA
demonstrated that TRU-015 was generally well tolerated and
resulted in dose-dependent B-lymphocyte depletion [6]. The
present study was designed to further assess the safety and
pharmacokinetics of TRU-015 and to additionally evaluate clinical
responses in RA subjects with active disease treated with
TRU-015.
Methods Thirty-six RA subjects with active disease despite
background methotrexate were enrolled in this randomized,
double-blind, multicenter, placebo-controlled study. Subjects were
enrolled into one of three cohorts in a 10:2 (active:placebo) ratio to
receive TRU-015 as a single intravenous infusion of 5 mg/kg, two
infusions of 2.5 mg/kg, or two infusions of 7.5 mg/kg. Subjects in
cohorts with two infusions received the infusions 1 week apart.
Subjects were premedicated with steroids, but only peri-infusional
doses were used.
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Pharmacokinetics of TRU-015
Area under  Maximum 
the curve from  concentration  Coefficient 
Group  time 0 to infinity  of drug  Half-life  of variability 
(mg/kg) (μg/h/ml) (μg/ml) (hours) (%)
0.5 1,342 13.8 281 59.1
1.5 7,082 58.2 282 26.5
5 18,140 154 295 33.4
15 71,753 462 409 32.8S15
Results Interim data are available in this ongoing study. TRU-015
was generally well tolerated. No significant infusion reactions were
observed. No infectious or noninfectious serious adverse events
related to TRU-015 have been reported. B-cell depletion was
demonstrated in all cohorts. The exposure of TRU-015 following
two intravenous infusion of 2.5 mg/kg was comparable with that
following a single infusion of 5 mg/kg. ACR20 responses have been
observed in 72% of all evaluable subjects and 82% of rheumatoid
factor-positive subjects. At 12 weeks, response rates were similar in
each of the cohorts. Longer-term observation is ongoing.
Conclusion TRU-015, administered at doses resulting in B-cell
depletion, is generally well tolerated. No significant safety issues
have been observed. This study provides evidence that therapy
with TRU-015 results in meaningful clinical benefit in subjects with
active RA despite methotrexate therapy. Further exploration is
required to determine the optimal dose of TRU-015.
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Background All candidates for anti-TNF treatment should undergo
screening for latent tuberculosis infection (LTBI). BCG vaccination
may lead to a positive tuberculin skin test (TST) and false diagnosis
of LTBI. Conversely, some immunosuppressed patients may not
respond to a TST. Quantiferon TB-Gold (QFT-G) is a new
screening tool that uses a peptide cocktail simulating ESAT-6,
CFP-10 and TB7.7(p4) proteins to stimulate cells in heparinised
whole blood. Detection of IFNγ by ELISA is used to identify in vitro
responses to these peptide antigens that are specifically
associated with Mycobacterium tuberculosis infection and do not
cross-react with immunity induced by BCG.
Objective To assess the performance of the QFT-G test for
screening before the initiation and also during anti-TNF treatment.
Methods The QFT-G test (intube method) was used to determine
IFNγ production after stimulation with MT-specific antigens (ESAT-
6, CFP-10 and TB7.7(p4) proteins) as well as with nonspecific
mitogen (PHA). Altogether, 317 patients were investigated
(rheumatoid arthritis (RA) = 117, ankylosing spondylitis (AS) = 95,
adult juvenile idiopathic arthritis (JIA) = 54, Crohn’s disease (CD) =
30, and psoriatic arthritis (PsA) = 21). Fifteen AS patients
completed QFT-G assessments prior to anti-TNF and also after 2
and 14 weeks of treatment (before the second and fourth infliximab
infusions). One hundred and eight patients had the QFT-G only
before they started anti-TNF, six patients before and during
therapy, and 203 patients only during the treatment. Tuberculin
2TU was used for the TST and results were read after
48–72 hours.
Results Out of the total 317 tests, 12 (3.8%) were indeterminate
(5 x CD, 4 x RA, 2 x JIA, 1 x AS) (two high spontaneous IFNγ
production, 10 low mitogen response). Eleven out of these 12
patients were on combined immunosuppression. Twelve patients
(10.5%) (5 x RA, 4 x AS, 2 x CD, 1 x JIA) were positive in the QFT-
G in the screening. Four had a negative TST, five a positive, in two
the TST was unavailable. From 209 patients investigated during
the treatment, 12 were QFT-G-positive. In three of them the initial
pretreatment status was known and the QFT-G was negative;
however, all three were positive in the TST at 16, 7 and 10 mm.
Two of them became QFT-G-positive before the second infliximab
infusion, one before the fourth infusion. The remaining nine positive
patients had longstanding treatment with different anti-TNF
biologicals.
In patients with a positive TST (n = 64), 30 had the QFT-G done
before treatment – five had positive results and one an
indeterminate result. The remaining 34 TST-positive patients were
QFT-G-positive in nine cases and one result was indeterminate. In
those who were TST-negative (n = 100), five were positive for the
QFT-G. One patient developed TB, TST-negative, QFT-G-positive
before therapy.
In patients who were on infliximab and repeatedly investigated,
IFNγ production after the nonspecific mitogen stimulation
increased: 6.7 ± 3.8 IU/ml, 8.4 ± 2.6 IU/ml, and 8.9 ± 3.4 IU/ml
(P = 0.001) before treatment and after 2, and 12 weeks,
respectively. No difference was found in IFNγ in longitudinal
samples after stimulation with TB antigens.
Conclusion There is scarce information about QFT-G use before
and during anti-TNF treatment. Our first experience shows that the
QFT-G may be more sensitive and specific for LTBI detection than
the TST, although its real usefulness for screening before anti-TNF
treatment needs to be assessed in long-term studies. The QFT-G
is valuable once anti-TNF has been initiated as we detected a
relatively high number of positive patients who may be in danger of
TB development. No decrease of the mitogen-induced capacity in
IFNγ production shows that test can be meaningfully used during
anti-TNF treatment.
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Peroxisome proliferator-activated receptor gamma 1
expression is diminished in human osteoarthritis cartilage and
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Peroxisome proliferator-activated receptor gamma (PPARγ) is a
nuclear receptor involved in the regulation of many cellular
processes. We and others have previously shown that PPARγ
activators display anti-inflammatory and chondroprotective
properties in vitro and improve the clinical course and histopatho-
logical features in an experimental animal model of osteoarthritis
(OA). However, the expression and regulation of PPARγ
expression in cartilage are poorly defined. This study was under-
taken to investigate the quantitative expression and distribution of
PPARγ in normal and OA cartilage and to evaluate the effect of
IL-1β, a prominent cytokine in OA, on PPARγ expression in
cultured chondrocytes.
Immunohistochemical analysis revealed that the levels of PPARγ
protein expression were significantly lower in OA cartilage when
compared with normal cartilage. Using real-time RT-PCR, we
demonstrated that PPARγ1 mRNA levels were ~10-fold higher
than PPARγ2 mRNA levels; and that only PPARγ1 was differentially
expressed, its levels in OA cartilage being 2.4-fold lower than in
normal cartilage (P < 0.001). IL-1 treatment of OA chondrocytes
downregulated PPARγ1 expression in a dose-dependent and time-
dependent manner. This effect probably occurred at the trans-
criptional level, since IL-1 decreases both PPARγ1 mRNA
expression and PPARγ1 promoter activity. TNFα, IL-17, and
prostaglandin E2, which are involved in the pathogenesis of OA,
also downregulated PPARγ1 expression. Specific inhibitors of the
mitogen-activated protein kinase (MAPK) p38 (SB203580) and
JNK (SP600125), but not Erk (PD98059), prevented IL-1-induced
downregulation of PPARγ1 expression. Similarly, inhibitors of NF-
κB signaling (PDTC, MG-132, and SN-50) abolished the
suppressive effect of IL-1. In conclusion, our study has demon-
strated for the first time that PPARγ1 is downregulated in OA
cartilage. The proinflammatory cytokine IL-1 may be responsible for
this downregulation via a mechanism involving activation of the
MAPKs (p38 and JNK) and NF-κB signaling pathways. The IL-1-
induced downregulation of PPARγ expression might be a new and
additional important process by which IL-1 promotes articular
inflammation and cartilage degradation.
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Background Osteoarthritis (OA) is characterized by cartilage
damage and loss, synovial membrane inflammation, and bone
sclerosis and the formation of osteophytes. Bone sclerosis in OA is
due to an abundant osteoid matrix that does not mineralize
normally. The mechanism(s) responsible for this abnormal
mineralization remain unknown. Here, we studied the link between
the mineralization profile of normal and OA osteoblasts (Ob) in
primary culture and the mechanisms responsible for this abnormal
sclerosis.
Materials and methods We prepared normal and OA Ob from
subchondral bone of tibial plateaus. The expression of collagen
type 1 α1 chains (COLL1A1) and α2 chains (COLL1A2) was
determined by real-time PCR. In vitro mineralization was evaluated
by alizarin red staining. We also determined the mineralization of
human SaOS-2 cells, either transfected with the COLL1A1 cDNA
or with siRNA for α1 chains. Conditioned-media (CM) from OA Ob
was used to alter the mineralization of SaOS-2 cells while SaOS-2
CM was used to determine whether this could correct OA Ob
mineralization.
Results In vitro mineralization was reduced in OA Ob compared
with normal Ob under basal conditions and following BMP-2
stimulation. This reduced mineralization was accompanied with an
increase in COLL1A1 expression in OA Ob compared with normal,
with no significant changes in COLL1A2, leading to an elevated
COLL1A1 to COLL1A2 ratio in OA Ob. To determine the link
between this ratio and mineralization, we used the SaOS-2 cell
model. The COLL1A1 to COLL1A2 ratio in SaOS-2 cells varied
from 7.5 to 1.5 from day 1 to day 14 postconfluence whereas
mineralization progressively increased. Overexpressing COLL1A1
in SaOS-2 cells reduced whereas α1 chains siRNA transiently
increased mineralization. In addition, SaOS-2 CM increased OA
Ob mineralization while OA Ob CM reduced mineralization of
SaOS-2 cells without any significant changes in the COLL1A1 to
COLL1A2 ratio.
Discussion This study suggests that abnormal mineralization of
OA bone tissue observed in vivo may be linked with an abnormal
expression of COLL1A1 and with the release of a putative soluble
factor by OA Ob. Production of an abnormal collagen matrix and a
soluble factor by OA Ob leads to an abnormal osteoid matrix not
mineralizing normally.
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Background Leptin is a peptide hormone with a role in body
weight regulation, immune response, bone metabolism and
possibly in rheumatic diseases. Osteoarthritis (OA) is charac-
terized by cartilage damage and loss, synovial membrane
inflammation and bone sclerosis and the formation of osteophytes.
It is now evident that the subchondral bone tissue plays a
prominent role in the pathophysiology of OA, a situation that is
related to abnormal osteoblast (Ob) differentiation. Leptin can
promote the differentiation of Obs; however, a direct role for leptin
in human OA has yet to be demonstrated.
Materials and methods We prepared primary cultures of normal
and OA Obs from subchondral bone and OA chondrocytes from
articular cartilage from tibial plateaus removed for knee
replacement surgery of OA patients or at autopsy. We determined
the expression and production of leptin using RT-PCR and ELISA.
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Alkaline phosphatase activity was determined by p-nitrophenyl
phosphate hydrolysis, osteocalcin release by enzyme immunoassay
and collagen production by the release of the CICP propeptide.
TGFβ1 production was determined by ELISA. Inactivating
antibodies raised against leptin receptors and inhibitors of leptin
signaling, typhostin (Tyr) and piceatannol (Pce) were used to
determine their effect on Ob cell markers. Cellular proliferation was
assessed using the BrdU cell proliferation assay whereas
activation of the Erk1/2 pathway was determined by western blot
analysis.
Results Our results indicated using two different sets of primers
for RT-PCR experiments that leptin was expressed only in Obs not
in chondrocytes. The expression of leptin was also higher in OA
Obs compared with normal using real-time PCR and was
responsible for the increase in leptin levels noted in conditioned-
media from OA Obs. Although leptin was not expressed by
chondrocytes, it was present in articular cartilage – suggesting
that leptin produced in bone tissue reached the overlaying
cartilage. The long-form leptin receptor mRNA levels were slightly
reduced in OA Obs compared with normal Obs. Since leptin can
promote the differentiation of Obs, we next questioned whether the
observed increase in alkaline phosphatase activity (ALP) and
osteocalcin release (OC) observed in OA Obs was linked with
their endogenous leptin production. Inactivating antibodies against
the leptin receptor reduced both ALP and OC in OA Obs about
35%, a situation reproduced with Tyr and Pce. Likewise, Tyr and
Pce also reduced ALP, CICP release, and TGFβ1 production in
OA Obs. Last, leptin dose-dependently (1 ng/ml to 10 mg/ml)
stimulated cellular proliferation in OA Obs and this was reflected
by an increase in phosphorylation of Erk1/2 signaling.
Discussion These results indicate that OA Obs produce more
leptin than normal, and suggest that leptin found in articular
cartilage is derived from bone tissue. The increase in leptin in OA
bone tissue could also be responsible for increased ALP, OC and
TGFβ1 in Obs. Since leptin can promote inflammation and cartilage
loss in combination with cytokines, this suggests that subchondral
bone production of leptin may be responsible, at least in part, for
cartilage loss in OA.
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Background Nonsynonymous polymorphisms in the human FRZB
gene have been associated with osteoarthritis (OA). In addition, a
differential association between OA and osteoporosis (OP) has
been reported. We have demonstrated that genetic deletion of the
Frzb gene in mice increases cartilage damage in different models
of OA. In addition, Frzb–/– mice show increased cortical bone
density.
Objective To study the underlying molecular mechanisms involved
in cartilage damage and increased bone density in Frzb–/– mice.
Methods Active Wnt signaling in the articular cartilage was
studied in normal and methylated bovine serum albumin, colla-
genase and papain-induced arthritis using β-catenin (CTNNB1)
immunohistochemistry. Gene expression patterns of components
of the Wnt signaling pathway, its antagonist and target genes,
were studied using multigene cDNA arrays (Superarray) in
microdissected articular cartilage and soft tissues of healthy and
affected knees from Frzb–/– and wild-type mice. Gene expression
of tissue destructive enzymes in the cartilage was studied by real-
time PCR. Matrix metalloproteinase-3 activity was tested in vitro.
Cortical bone stiffness was estimated by compression of the ulnae.
Mechanical loading-induced bone adaptation was studied by
compression of the ulnae of 17-week-old mice, followed by
microcomputed tomography analysis at a resolution of 5 ìm.
Subchondral bone properties were studied with histomorphometry,
peripheral quantitative computed tomography and microcomputed
tomography.
Results In healthy cartilage of Frzb–/– mice, four genes were
consistently expressed at lower levels than in the wild-type mice:
Ctnnb1, Ctbp1, Fosl1 and Myc. In contrast, Wnt8b expression
was upregulated in healthy cartilage in 2/3 samples from Frzb–/–
versus wild-type mice and in all samples in affected versus healthy
wild-type cartilage. Ctbp1 and Fosl1 were also downregulated in
all samples from arthritic wild-type mice versus healthy ones. In
addition, Wnt8b appears to be downregulated in arthritic versus
healthy joints of Frzb–/– mice, suggesting a distinct regulation of
Wnt ligand expression in the genetic model as compared with the
wild-type mice. Cartilage damage in Frzb–/– mice is associated with
increased canonical Wnt signaling, matrix metalloproteinase-3
expression and activity. In addition, the Frzb–/– mice have an
increased cortical bone thickness and density, resulting in stiffer
bones as demonstrated by a different stress–strain relationship in
Frzb–/– mice. Moreover, the periosteal anabolic response to
mechanical loading is significantly greater in Frzb–/– mice than in
wild-type mice. FRZB is expressed in the periosteum.
Conclusion The preinduction gene expression profile in Frzb–/–
mice shows similarities with arthritic cartilage in wild-type mice.
Loss of Frzb may contribute to cartilage damage by increased
expression and activity of matrix metalloproteinase in both a Wnt-
dependent and Wnt-independent manner. FRZB deficiency also
results in thicker cortical bone with increased stiffness and higher
cortical appositional bone formation after loading. This may
contribute to OA by producing increased strain on the articular
cartilage during locomotion. Increased cortical density of long
bones in Frzb–/– mice supports our earlier observation that
polymorphisms in the human FRZB gene are differentially
associated with hip OA and OP hip fractures. The role of FRZB in
cartilage and bone biology may therefore provide a mechanistic
basis for the longstanding clinical observation that OA and OP
show an inverse relationship.
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Chondrocyte differentiation into hypertrophic chondrocytes is
essential for enchondral ossification of long bones during limb
development, but plays a role also in pathologic situations such as
osteoarthritis (OA). However, the mechanisms that link chondro-
cyte hypertrophy to cartilage remodeling are poorly understood.
Based on recent data that have implicated transmembrane
Available online http://arthritis-research.com/supplements/9/S3S18
heparan sulfate proteoglycans in matrix turnover and cell differen-
tiation, we analyzed the role of syndecan-4 during limb develop-
ment in mice and studied its expression and function in OA.
Syndecan-4 promoter activity was detected in whole embryos by
staining for β-galactosidase in syndecan-4–/– LacZ knockin mice.
For cellular localization of syndecan-4 expression within cartilage,
immunohistochemistry with antibodies against syndecan-4 and
type X collagen was performed. Alizarin red S staining was carried
out to analyze the mineralization of bones in wild-type and
syndecan-4–/– littermates at days E13.5 and E14.5. To study
syndecan-4 in OA, we compared its expression in normal and OA
articular cartilage by Northern blot analysis and immunohisto-
chemistry. Blocking antibodies against syndecan-4 were generated
and used to analyze the role of syndecan-4 in IL-1-mediated
proteoglycan loss in vitro. For functional analysis in vivo, osteo-
arthritic changes were induced in syndecan-4–/– mice and in wild-
type controls by surgically achieved joint instability, and the loss of
proteoglycans was assessed by safranin-orange staining. Staining
for syndecan-4 and ADAMTS-generated aggrecan neo-epitopes
was performed in the knees of these mice.
β-Galactosidase-staining of syndecan-4–/– mice at E12.0 showed
a strong activity of the syndecan-4 promoter at sites of cartilage
condensations. In later stages, syndecan-4 was detected in the
growth plates of long bones. In wild-type embryos, syndecan-4
protein was also found mainly in chondrocytes of the hypertrophic
zone, where it colocalized with type X collagen. The loss of
syndecan-4 was associated with a significant retardation in the
mineralization of axial and appendicular bones. Interestingly, there
was a clear upregulation of syndecan-4 in human OA cartilage
both at the mRNA and the protein level. In the cartilage explant
model, blocking antibodies to syndecan-4 substantially significantly
reduced the IL-1-induced loss of proteoglycans in wild-type
cartilage. Analysis of OA-like changes in mice revealed a strong
and early induction of syndecan-4, and there was a significant
reduction of proteoglycan loss in the syndecan-4–/– mice compared
with their wild-type controls. This was accompanied by a
significantly reduced staining for ADAMTS-generated aggrecan
neo-epitopes in syndecan-4–/– mice.
Our data show that syndecan-4 is induced in hypertrophic
chondrocytes both during embryogenesis and in OA cartilage. By
promoting ADAMTS-mediated cleavage of aggrecans, syndecan-4
facilitates enchondral ossification but is involved also in cartilage
degradation by hypertrophic chondrocytes in OA. Inhibition of
syndecan-4 may therefore constitute a promising strategy to
interfere with osteoarthritic cartilage damage.
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Objective To characterise the catabolic response of osteoarthritic
(OA) chondrocytes to ligands that activate the complete repertoire
of Toll-like receptors (TLRs).
Methods The induction of MMP-1 and MMP-13, the collagenases,
by ligands that activate the complete repertoire of TLRs was
assessed in OA chondrocytes by quantitative RT-PCR. TLR ligand
signalling pathway activation and their role in collagenase induction
was analysed by western blotting and selective pathway inhibitors
and siRNA. TLR ligand expression was compared in total RNA
from femoral head cartilage of normal (neck of femur fracture) and
OA patients undergoing joint replacement surgery.
Results All the ligands upregulated MMP-1 and MMP-13, although
to differing degrees, indicating differential regulation of the
collagenases and indicating that chondrocytes express most TLRs.
MALP-2 (TLR6/2 ligand) and poly(IC) (a dsRNA mimicking TLR3
ligand) most robustly upregulated MMP-1 and MMP-13,
respectively. Using siRNA the activation of MMP-13 by TLR3 and
TLR6/2 ligands were confirmed to be via the adaptor Trif and
MyD88. The induction of both MMP-1 and MMP-13 by TLR1/2,
TLR3 and TLR6/2 ligands were dependent upon the NF-κB
pathway. Interestingly, MMP-1 and MMP-13 induction by the three
TLR ligands were differentially inhibited by various MAPK inhibitors,
with MMP-13 induction sensitive to ERK pathway inhibition. In a
cartilage resorption assay, TLR1/2 and TLR6/2 ligands, but not
TLR3 ligand, led to significant collagen release. The expression
profile of TLRs in neck of femur and OA cartilage revealed a highly
significant (P < 0.001) downregulation of TLR2 and upregulation
of TLR3.
Conclusion Our gene expression profile reveals that chondrocytes
express a large repertoire of TLRs, which upon activation leads to
collagenase gene activation. The TLR1/2 and TLR6/2 ligands,
which resulted in cartilage collagen resorption, require TLR2,
whose expression is significantly repressed in end-stage OA.
These data suggest modulation of TLR-mediated signalling,
particularly via TLR2, as a potential therapeutic strategy for OA
prevention.
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